跳至主要内容
临床试验/NL-OMON51867
NL-OMON51867已完成不适用

The intracellular pharmacokinetics of tacrolimus in CD3+ T lymphocytes - INTACT

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 31 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
31

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age * 18 years.
  • - Recipient of a kidney transplant at the Erasmus MC.
  • - Use once-daily tacrolimus as part of routine maintenance immunosuppression
  • starting the day of surgery.
  • - Written informed consent.

排除标准

  • Patients who receive lymphocyte depleting agents (thymoglobuline,
  • anti-thymocyte globulin, and alemtuzumab) as an induction therapy or
  • anti-rejection treatment before enrolment. Recipients using medication known to
  • have a pharmacokinetic (drug-drug) interaction with tacrolimus: Antibiotics
  • (Clarithromycin, Doxycyclin, Erythromycin, Rifampicin), Antiepileptics
  • (Carbamazepine, Phenobarbital, Phenytoin), Antihypertensive and antiarrhythmic
  • agents (Amiodarone, Diltiazem, Verapamil), Antimycotic drugs (Fluconazole,
  • Itraconazole, Ketoconazole), Other (HIV protease inhibitors, Theophyllin)

研究者

相似试验